166 related articles for article (PubMed ID: 12911582)
1. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?
Brown SA; Eldridge A; Collins PW; Bowen DJ
J Thromb Haemost; 2003 Aug; 1(8):1714-7. PubMed ID: 12911582
[TBL] [Abstract][Full Text] [Related]
2. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
3. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.
Callan MB; Giger U; Catalfamo JL
Am J Vet Res; 2005 May; 66(5):861-7. PubMed ID: 15938072
[TBL] [Abstract][Full Text] [Related]
4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
5. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
[TBL] [Abstract][Full Text] [Related]
6. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders.
Nolan B; White B; Smith J; O'Reily C; Fitzpatrick B; Smith OP
Br J Haematol; 2000 Jun; 109(4):865-9. PubMed ID: 10929043
[TBL] [Abstract][Full Text] [Related]
7. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
8. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
9. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
Sztukowska M; Gallinaro L; Cattini MG; Pontara E; Sartorello F; Daidone V; Padrini R; Pagnan A; Casonato A
Br J Haematol; 2008 Oct; 143(1):107-14. PubMed ID: 18691167
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
12. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
Guddati AK; Rosovsky RP; Van Cott EM; Kuter DJ
Int J Lab Hematol; 2019 Jun; 41(3):325-330. PubMed ID: 30735311
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration.
de Jager NCB; Heijdra JM; Kieboom Q; Kruip MJHA; Leebeek FWG; Cnossen MH; Mathôt RAA;
Thromb Haemost; 2020 Oct; 120(10):1407-1416. PubMed ID: 32746466
[TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.
Favaloro EJ; Kershaw G; Bukuya M; Hertzberg M; Koutts J
Haemophilia; 2001 Mar; 7(2):180-9. PubMed ID: 11260278
[TBL] [Abstract][Full Text] [Related]
17. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
18. Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.
Ragni MV; Novelli EM; Murshed A; Merricks EP; Kloos MT; Nichols TC
Thromb Haemost; 2013 Feb; 109(2):248-54. PubMed ID: 23238591
[TBL] [Abstract][Full Text] [Related]
19. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
Santiago-Borrero PJ; Casanova R
Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
[TBL] [Abstract][Full Text] [Related]
20. Intraleucocyte platelet-activating factor levels in desmopressin-treated patients with haemophilia A and von Willebrand disease.
Kavakli K; Hüseyinov A; Coker I; Aydinok Y; Nisli G
Haemophilia; 2001 Sep; 7(5):482-9. PubMed ID: 11554936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
